Expanding Access to Medical Maintenance Treatment

We reported on the Association’s criteria for implementing a policy for referring stabilized methadone maintained patients from treatment programs to off-site physician based settings during the previous News Report of August, 1998. We recognize the challenges of implementing such a new referral system, especially in view of the history of restricting methadone treatment to licensed and regulated treatment programs.

We remind our readers that the underlying motivation for this policy was to provide stabilized patients with an option to receive their continued care in a setting that is different from the methadone treatment program. We have consulted with patient advocacy groups, including the National Alliance of Methadone Advocates (NAMA), and we have been informed that such options would be favorably received by stabilized patients in treatment settings.

The Connecticut Pilot project, which refers stabilized patients to
off-site medical settings, has been in existence for over a year and it is hoped that the state of Connecticut will be able to file a report with the Center for Substance Abuse Treatment (CSAT) about its progress very shortly.

The value of expanding access to medical maintenance treatment is to free up critically needed treatment slots for the untreated opiate dependent individuals, who need access to methadone treatment services. The Association’s criteria have been listed below and may seem conservative at first sight. We have always taken the view that this policy represents the first logical step in a long-term strategic plan, which will work in conjunction with other medications as well, such as Buprenorphine.

A number of people have cited international findings regarding methadone maintenance in physician offices, criticizing the Association’s policy as being rigid. We have received conflicting information about the success of such initiatives in Europe and Australia. Dr. John Caplehorn (Australia) has published findings about methadone related deaths in Australia as undertrained physicians prescribe methadone to newly admitted opiate dependent patients.

We continue to hold to the principles that certified physicians should be involved in treating methadone maintained patients in their private practice settings through this hub referral mechanism in addition to physicians who have demonstrated a knowledge in working with methadone maintenance treatment as documented by a two year involvement in a treatment program. We will continue to work with CSAT and other federal agencies to begin the process of referring such patients to private practice settings, however, a functioning treatment network needs to be established in order to implement this policy.

Criteria for Stable Patient Referral from Methadone Programs to Office Based Medical Practice Settings
“Expanding Access to Medical Maintenance Treatment”

Program Involvement: (We recommend the following criteria for choosing the participating agencies):

  • Compliance with federal and state regulatory authorities.
  • Adherence to CSAT’s State Methadone Treatment Guidelines and the American Methadone Treatment Association’s Ethical Canon.
  • Licensed as a “Narcotic Treatment Program” for a minimum of two years.
  • Demonstrated internal protocols for reviewing patient eligibility, utilizing a multidisciplinary team approach including, at a minimum, the program’s Medical Director, Nurse Manager, and the patient’s counselor.
  • The program shall contract with the participating physicians.

Physician Involvement: (Demonstrated interest in the treatment of opioid dependent patients in his/her medical or psychiatric practices as defined by):

  • Certification by the American Board of Psychiatry and Neurology with subspecialty certification in addiction psychiatry, certification by the American Society of Addiction Medicine (ASAM) or Specialty Board Certification of Physicians of the American Osteopathic Association. It is recommended that physicians with such certification sit for a course on opioid pharmacotherapy as offered by the American Methadone Treatment Association or a recognized medical society.
  • Physicians without such certification, but with a documented two-year involvement in a methadone treatment program, should sit for a course on opioid pharmacotherapy as offered by the American Methadone Treatment Association or a recognized medical society
  • Knowledge of specific methadone prescribing practices as regulated by state and federal law.
  • Practices consistent with CSAT’s State Methadone Treatment Guidelines.
  • Agreement to provide progress reports to the sponsoring “Narcotic Treatment Program”.
  • Agreement to work with the patient and program regarding relapses or unstable patients.
  • Provision for urine screens.
  • No pending state licensure actions against the participating physician.
  • Proof of minimum individual professional liability coverage as required by the State Medical Board of Examiners or equivalent thereof.

Patient Eligibility: (The patient must meet the following criteria):

  • Patient be physically and emotionally stable for 36 months.
  • The patient should be free of alcohol and drug abuse for 36 months verified by toxicology screening.
  • The patient has not been convicted of any criminal activity for 36 months.
  • The patient has been employed or in a similar capacity (a student, homemaker or disabled) for 36 months as well as a stable living environment.
  • Demonstrated responsible use of take home methadone through a participating licensed “Narcotic Treatment Program”.

There may be exceptions granted to the 36 month criteria. Exceptions must be based on the individual’s progress in treatment and recommendations made by the treatment team as documented in the clinical record. The process for which this decision can be made must be endorsed and reviewed by the State Regulatory Authority.

Organizational Issues:

  • Professional and agency liability:
  • A copy of the physician’s professional liability insurance would be included in the physician’s file, which would be kept at the program site.
  • Professional liability coverage would be incorporated into the contractual agreement with participating physicians.

Methadone distribution to participating physicians:

  • The participating physicians will be registered under the umbrella of the narcotic treatment program license.
  • A personnel file with resumes, license, registration numbers, personal professional liability insurance carrier, and contract to provide this service would be on file with the program.
  • The administration and dispensing of methadone hydrochloride in an “off-site” physician based practice will require a change in federal and state laws and regulations.

Discontinuation of off-site services: (Patients will be referred back to the base “Narcotic Treatment Program” for continued services for the following reasons):

  • Signs and/or symptoms of recurring drug or alcohol misuse.
  • Negative methadone urine screens or positive for drugs not appropriately prescribed.
  • Significant changes in mental/physical/behavioral status that would require more patient supervision.
  • NonEvidence of criminal activity (drug or other).compliance with medical care.

The Board of Directors of the American Methadone Treatment Association formed a Program Management Committee during 1997 to develop a series of training symposia for program managers. The Association convened the first management-training symposium in Washington, DC on December 8, 1998 with the assistance of an educational grant from Glaxo Wellcome, Inc.

The symposium began the process of highlighting the Association’s hallmark policy issues in improving the quality of care in methadone treatment programs across the United States:

  • implementing meaningful patient satisfaction survey instruments;
  • changing staff attitudes and improving patient outcome-implementing staff attitudinal surveys;
  • preparing methadone treatment programs for accreditation;
  • implementing pro active media and public relations strategies in methadone treatment; and
  • preventing medical negligence claims in methadone treatment programs
@aatod1984
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
  • #aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
  • Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
  • Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
  • Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
  • Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
  • Final Opportunity to Submit Proposals for the #aatod2024 Conference. The submission window will close tonight at 12am ET.

To submit a proposal, please follow the on-screen instructions, bit.ly/3KxQSzU. For questions or additional information regarding the Call for Presentations, please send an email to meetings@aatod.org or call 856-423-3091.

We look forward to receiving your submissions and hope to see you at the conference for what will be the premier conference on the treatment of opioid use disorders in 2024! #morethanmedicine #programnotapill #opioids #OUD #OpioidUseDisorder #submitproposal
  • Today is the Final Day to Submit Proposals for the #aatod2024 conference, 9/21 ➡️ bit.ly/3KxQSzU

The Workshop Committee encourages you to submit proposals on innovative initiatives to enhance patient outcomes, improve program development and administration, promote integration across the continuum of care, and the development of collaborations with organizations outside of the traditional opioid treatment system.

Conference Objectives:
1️⃣Conduct a comprehensive review of the latest evidence addressing the opioid epidemic and its implications for patients, clinicians, administrators, and policy makers by identifying the most effective interventions.
2️⃣Discuss peer to peer approaches in treating opioid use disorder in an effort to improve patient outcomes in health systems, organizations, and communities.
3️⃣Evaluate the gaps in current services for opioid use disorder and develop recommendations to improve the delivery of multidisciplinary care in various populations based upon evidence-based practices.
4️⃣Disseminate a comprehensive plan of innovative services designed to treat emerging needs of patients with opioid use disorder and improve patient outcomes by providing examples of effective methods and how to implement them.
5️⃣Identify effective referral pathways to other health services offering treatment for conditions associated with opioid use disorder addiction and/or recovery by developing partnerships within the community.
  • We are pleased to announce that the deadline for submitting presentations for the #aatod2024 Conference has been extended to Thursday, September 21, 2023.

We encourage all interested parties to take advantage of this opportunity and submit their proposals as soon as possible. We look forward to receiving your proposals and to seeing you in Las Vegas in 2024. 

https://conta.cc/3PiV5ck
  • August 31st is International Overdose Awareness Day 
💜 #IOAD2023 
💜 #NaloxoneSavesLives 
💜 #EndOverdoseNow

Please contact your State Opioid Treatment Authority for locations in your community that distribute naloxone kits —> bit.ly/3qVPOPz. 

 Full Video 🎥 bit.ly/3ElzdYD
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024 TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD. For registration and hotel information ➡️ bit.ly/3Ue57Q6. We look forward to seeing you in Las Vegas!
3 weeks ago
View on Instagram |
1/10
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6. The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment. The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders. We hope to see you in Las Vegas!
4 weeks ago
View on Instagram |
2/10
Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
Patient access to OTPs saves lives every day. AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
3 months ago
View on Instagram |
3/10
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. “Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA Read More ➡️ bit.ly/3tKb1gy
4 months ago
View on Instagram |
4/10
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery. Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1 For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
4 months ago
View on Instagram |
5/10
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. Register ➡️ bit.ly/461CkkG
5 months ago
View on Instagram |
6/10
Final Opportunity to Submit Proposals for the #aatod2024 Conference. The submission window will close tonight at 12am ET. To submit a proposal, please follow the on-screen instructions, bit.ly/3KxQSzU. For questions or additional information regarding the Call for Presentations, please send an email to meetings@aatod.org or call 856-423-3091. We look forward to receiving your submissions and hope to see you at the conference for what will be the premier conference on the treatment of opioid use disorders in 2024! #morethanmedicine #programnotapill #opioids #OUD #OpioidUseDisorder #submitproposal
5 months ago
View on Instagram |
7/10
Today is the Final Day to Submit Proposals for the #aatod2024 conference, 9/21 ➡️ bit.ly/3KxQSzU The Workshop Committee encourages you to submit proposals on innovative initiatives to enhance patient outcomes, improve program development and administration, promote integration across the continuum of care, and the development of collaborations with organizations outside of the traditional opioid treatment system. Conference Objectives: 1️⃣Conduct a comprehensive review of the latest evidence addressing the opioid epidemic and its implications for patients, clinicians, administrators, and policy makers by identifying the most effective interventions. 2️⃣Discuss peer to peer approaches in treating opioid use disorder in an effort to improve patient outcomes in health systems, organizations, and communities. 3️⃣Evaluate the gaps in current services for opioid use disorder and develop recommendations to improve the delivery of multidisciplinary care in various populations based upon evidence-based practices. 4️⃣Disseminate a comprehensive plan of innovative services designed to treat emerging needs of patients with opioid use disorder and improve patient outcomes by providing examples of effective methods and how to implement them. 5️⃣Identify effective referral pathways to other health services offering treatment for conditions associated with opioid use disorder addiction and/or recovery by developing partnerships within the community.
5 months ago
View on Instagram |
8/10
We are pleased to announce that the deadline for submitting presentations for the #aatod2024 Conference has been extended to Thursday, September 21, 2023. We encourage all interested parties to take advantage of this opportunity and submit their proposals as soon as possible. We look forward to receiving your proposals and to seeing you in Las Vegas in 2024. https://conta.cc/3PiV5ck
5 months ago
View on Instagram |
9/10
August 31st is International Overdose Awareness Day 💜 #IOAD2023 💜 #NaloxoneSavesLives 💜 #EndOverdoseNow Please contact your State Opioid Treatment Authority for locations in your community that distribute naloxone kits —> bit.ly/3qVPOPz. Full Video 🎥 bit.ly/3ElzdYD
6 months ago
View on Instagram |
10/10

Announcing groundbreaking updates: HHS/SAMHSA's new regulations mark a significant step forward for opioid treatment programs. Fostering enhanced accessibility, flexibility and patient dignity. Gratitude to @@AATOD1984 for their pivotal role in this progress. #OpioidTreatment

Load More...

2024 Conference Las Vegas

2024 Conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram

Stay Connected to AATOD